Literature DB >> 2045827

What is migraine? Controversy and stalemate in migraine pathophysiology.

J Edmeads1.   

Abstract

Theories of migraine pathophysiology have evolved from the realms of the supernatural into the scientific arena but their further evolution seems delayed by unproductive controversy about whether or not migraine is primarily a vascular or a neurological dysfunction. This conceptual deadlock needs to be transcended by thinking beyond the neural and vascular systems, and by identifying mechanisms that could affect both to produce the characteristic clinical phenomena of migraine. One theoretical model envisages 5-hydroxytryptamine (serotonin; 5-HT) as a link between the neural and vascular systems, with global alteration of serotonergic neurotransmission affecting not only these systems, but the gastrointestinal tract as well, with incidental reverberations on platelet function. Such altered serotonergic transmission might originate from altered 5-HT receptor dynamics, a molecular change in turn produced by genetic mechanisms. Recognition of the importance of 5-HT receptor function in migraine, most notably that agonists of 5-HT1 receptors abort acute migraine and that antagonists of 5-HT2 receptors prevent migraine, may lead to significant therapeutic advances. The possibility that the "trigeminovascular system" might be the end-stage mechanism that these serotonergic changes detonate to produce the painful reverberations of migraine headache is also important. Seeking ways to muffle these reverberations, or to insulate the system itself from the action of external influences (likely through further study of peptidergic transmission and receptors) might result in more drugs that will abort or prevent migraine.

Entities:  

Mesh:

Year:  1991        PMID: 2045827     DOI: 10.1007/bf01642898

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  Effect of serotonin in migraine patients.

Authors:  R W KIMBALL; A P FRIEDMAN; E VALLEJO
Journal:  Neurology       Date:  1960-02       Impact factor: 9.910

Review 2.  The pharmacology of current anti-migraine drugs.

Authors:  S J Peroutka
Journal:  Headache       Date:  1990-01       Impact factor: 5.887

3.  Anti-migraine drugs in development: advances in serotonin receptor pharmacology.

Authors:  P P Humphrey; W Feniuk; M J Perren
Journal:  Headache       Date:  1990-01       Impact factor: 5.887

4.  Relationships between headache and amine changes after administration of reserpine to migrainous patients.

Authors:  G Curzon; M Barrie; M I Wilkinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-12       Impact factor: 10.154

Review 5.  Migraine with and without aura: the same disease due to cerebral vasospasm of different intensity. A hypothesis based on CBF studies during migraine.

Authors:  T Skyhøj Olsen
Journal:  Headache       Date:  1990-04       Impact factor: 5.887

6.  Migraine: a platelet disorder.

Authors:  E Hanington; R J Jones; J A Amess; B Wachowicz
Journal:  Lancet       Date:  1981-10-03       Impact factor: 79.321

7.  5-Hydroxytryptamine levels and platelet aggregation responses in subjects with acute migraine headache.

Authors:  B P Hilton; J N Cumings
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-08       Impact factor: 10.154

8.  Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine.

Authors:  J Olesen; B Larsen; M Lauritzen
Journal:  Ann Neurol       Date:  1981-04       Impact factor: 10.422

9.  Serotonin S2 receptors and migraine: a study with the selective antagonist ICI 169,369.

Authors:  P T Davies; T J Steiner
Journal:  Headache       Date:  1990-05       Impact factor: 5.887

10.  The neurobiology of vascular head pain.

Authors:  M A Moskowitz
Journal:  Ann Neurol       Date:  1984-08       Impact factor: 10.422

View more
  7 in total

Review 1.  Therapeutic antibodies against CGRP or its receptor.

Authors:  Marcelo E Bigal; Sarah Walter; Alan M Rapoport
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

Review 2.  Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.

Authors:  Marcelo E Bigal; Sarah Walter
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 3.  5-Hydroxytryptamine and the pathophysiology of migraine.

Authors:  P P Humphrey
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 4.  Preclinical neuropharmacology of naratriptan.

Authors:  Geoffrey A Lambert
Journal:  CNS Drug Rev       Date:  2005

5.  Serotoninergic status in patients with hereditary vascular retinopathy syndrome.

Authors:  C W Storimans; D Fekkes; A van Dalen; E D Bleeker-Wagemakers; J A Oosterhuis
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

6.  Cortical-spreading depression: at the razor's edge of scientific logic.

Authors:  Vinod Kumar Gupta
Journal:  J Headache Pain       Date:  2011-01-11       Impact factor: 7.277

Review 7.  Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities.

Authors:  Parastoo Amiri; Somayeh Kazeminasab; Seyed Aria Nejadghaderi; Reza Mohammadinasab; Hojjat Pourfathi; Mostafa Araj-Khodaei; Mark J M Sullman; Ali-Asghar Kolahi; Saeid Safiri
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.